A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)
Latest Information Update: 05 May 2022
At a glance
- Drugs Mometasone/formoterol (Primary) ; Mometasone
- Indications Asthma
- Focus Adverse reactions
- Acronyms SPIRO
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Organon; Schering-Plough
- 08 Dec 2018 Results published in the Journal of Allergy and Clinical Immunology
- 23 May 2018 Results of a post-hoc analysis assessing asthma outcomes in a subgroup of patients who remained on the combination therapy (n=8447) presented at the 114th International Conference of the American Thoracic Society
- 16 Dec 2016 Status changed from active, no longer recruiting to completed.